Đo hoạt độ enzyme anpha- galactosidase A bằng phương pháp khối phổ để sàng lọc bệnh nhân fabry ở Việt Nam
Tóm tắt
Đo hoạt độ enzyme anpha- galactosidase A bằng phương pháp khối phổ để sàng lọc bệnh nhân fabry ở Việt NamTài liệu tham khảo
1. Albert A Hagege, Eric Caidron, [...], Dominique p Germain (2011), “Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study” Heart, 97(2), pp! 131-136.
2. Angela Dajnoki, Gyõrgy Fekete, Joan Keutzer, [...], Olaf Bodamer (2010), “Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometry”, Clínica Chimica Acta, 411(19-20), pp.1428-1431.
3. B. Sachdev, T. Takenaka, H. Teraguchi, c. Tei, p. Lee, W.J. McKenna and P.M (2002), “Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset hypertrophic cardiomyopathy”, Circulation, 105, pp. 1407-1411.
4. c. Ronald Scott, Susan Elliott, Norman Buroker, [...], Frantisek Turecek (2013), “Identification of Infants at Risk for Developing Fabry, Pompe, or Mucopolysaccharidosis-I from Newborn Blood Spots by Tandem Mass Spectrometry”, The Journal of Pediatrics, 163(2), pp.498-503.
5. Chang-Long Tai, Mei-Ying Liu, Hsiao-Chi Yu, [...], Dau-Ming Niu (2012), “The use of high resolution melting analysis to detect Fabry mutations in heterozygous females via dry bloodspots” Clínica Chimica Acta, 413, pp. 422-427.
6. Li Y, Scott CR, Chamóles NA, Ghavami A, Pinto BM, Turecek F, Gelb MH (2004), “Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening” Clinical Chemistry, 50 (10), pp. 1785-1796.
7. Liao HC, Chiang cc, Niu DM, Wang CH, Kao SM, Tsai FJ, Huang YH, Liu HC, Huang CK, Gao HJ, Yang CF, Chan MJ, Lin WD, Chen ỴJ (2014), “Detecting multiple lysosomal storage diseases by tandem mass spectrometry~a national newborn screening program in Taiwan”, Clínica Chimica Ada, 431, pp. 80 - 86.
8. Metz TF, Mechtler TP, Orsini JJ, Monica Martin, Shushan B, Herman JL, Ratschmann R, Item CB, Streubel B, Herkner KR, Kasper DC (2011), “Simplified newborn screening protocol for lysosomal storage disorders”, Clinical Chemistry, 57(9), pp. 1286 -1294.
9. Minje Han, Sun-Heejun, Sang Hoon Song, Kyoung Un Park, Jin Q_Kim, Junghan Song (2011),
“Use of Tandem Mass Spectrometry for Newborn Screening of 6 Lysosomal Storage Disorders in a Korean Population”, Korean J Lab Med, 31 (4), pp. 250 -256.
10. Nakao, Takenaka T, Maeda M, Kodama c, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H,Sakuraba H, et al (1995) “An atypical variant of Fabry’s disease in men with left ventricular hypertrophy”, The new england journal of medicine, 333(5), pp. 288-293.
11. Pamela Lavoie, Michel Boutin, and Christiane Auray-Blais (2013), “Multiplex Analysis of Novel Urinary Lyso-Gb3-Related Biomarkers for Fabry Disease by Tandem Mass Spectrometry”, Analytical chemistry, 85, pp. 1743-1752.
12. Scott CR, Elliott s, Buroker N, Thomas LI, Keutzer J, Glass M, Gelb MH, Turecek F (2013),
“Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry”, The Journal of Pediatrics, 163 (2), pp. 498 - 503. 13.Sheng-Hung Lee, Cheng-Fang Li, Hsiang-Yu Lin, Chien-Hsing Lin, Hao-Chuan Liu, Shih-Feng Tsai, Dau Ming Niu (2014), “High-throughput detection of common sequence variations of Fabry disease in Taiwan using DNA mass spectrometry”, Molecular Genetics and Metabolism, 11 l,pp.507-512. 14. Trisha A. Duffey, Garland Bellamy, Susan Elliott, Angela c. Fox, Michael Glass, FrantisekTurecek, Michael H. Gelb, c. Ronald Scott (2010), “A Tandem Mass Spectrometry Triplex Assay for the Detection of Fabry, Pompe, and Mucopolysaccharidosis-I (Hurler)”, Clinical chemistry, 56 (12), pp. 1854 -1861.
